Volume 20, Issue 4 (2-2007)                   Med J Islam Repub Iran 2007 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ghanei E, Nasrollahi A, Homayouni M, Rahbar K. Relationship between post-transplant lymphoproliferative disorder and Anti-Thymocyte Globulin or Anti-Lymphocyte Globulin. Med J Islam Repub Iran. 2007; 20 (4) :198-204
URL: http://mjiri.iums.ac.ir/article-1-388-en.html
Shahid Beheshti University of Medical Sciences,Shohad-e-Tajrish Hospital, Ghods sq, Tehran, Iran , dr-e-ghanei@Yahoo.com
Abstract:   (4457 Views)


 Background: Lymphoproliferative disorders are among the most serious and potentially fatal complications of chronic immunosuppression in kidney transplant recipients. The principle risk factors for development of PTLD are the degree of overall immunosuppression and the EBV serostatus of the recipient. In this study, the risk of PTLD in kidney transplant recipients who received Anti- Lymphocyte Globulin (ALG) or Anti Thymocyte Globulin (ATG) was evaluated.

 Methods: We retrospectively studied 520 patients who underwent kidney transplantation during the period from December 1989 to December 2002, at Taleghani Hospital, Tehran.

 Results: 369 patients received classic immunosuppression (prednisolone, cyclosporine, mycophenolate mofetil) and 151 patients (29%) received classic immunosuppression with ALG or ATG. Eight patients had developed PTLD, 5 cases of which (62.5%) received classic immunosuppression without ALG or ATG. Incidence of PTLD was 3.3 percent in patients who received ALG or ATG and 0.8 percent for those patients who did not receive ATG or ALG. This difference is very significant (p < 0.05).

 Conclusion: ALG or ATG therapy could act as a risk factor for PTLD.

Full-Text [PDF 27589 kb]   (779 Downloads)    
Type of Study: Original Research | Subject: Internal Medicine

Add your comments about this article : Your username or Email:

Send email to the article author